Biotech Currents
Bill LangbeinClinical & Regulatory Catalysts Driving BioPharma & MedTech Stocks Started by SanaCurrents ("SC"), a service established to identify which stocks, valued entirely on the promise of developing a new, novel drug, has the best chance for value appreciation.
| Platform |  | Pricing | Freemium | Publishes | Weekly |
|---|---|---|---|---|---|
| Issues | 210 | Subscribers | Read | biotechcurrents.substack.com |
Curious about how many subscribers Biotech Currents has or want to find similar newsletters? Reletter has got you covered. We collated all the information we could find from across the web in our database of over three million newsletters.
Check the email archives, get traffic estimates, engagement scores and more to discover the best advertising opportunities.
Our search tool helps you locate relevant newsletters for any topic and compare their stats for better sponsorship decisions.
Latest Issues
Recent posts by this newsletter. Browse the email archive.
Leukemia drug gains apparent safety advantage ahead of FDA decision
Assigning a 67.3% overall probability that the FDA will sign off.
Buyout candidates thrive, rare disease drug candidates dive
Companies with mature science such as kinase inhibitors and “zombie” biotechs – public companies that remain listed despite numerous failures – rarely thrive in the biopharma M&A market. Bidders typically prefer a company with an approved d...
The Friday Biotech Perspective #42
Shares of uniQure N.V. (NASDAQ:QURE) skyrocketed ~240% in late September after the company reported its drug AMT-130 demonstrated a statistically significant slowing of disease progression of Huntington’s disease (HD) in a phase I/II trial....
Pushing Gene Editing Inside the Body: A Company's New Approach to Treating B-Cell Cancers and Autoimmune Disease
Assigning a 65.3% overall probability data will be positive.
Similar Newsletters
Other publications recommended by the authors of this newsletter.
Authors
The writers behind this newsletter.
I am the founder of SanaCurrents, providing independent, catalyst-driven research on biopharma & medical device stocks. https://biotechcurrents.substack.com/
Frequently Asked Questions
How can I access the email archive for Biotech Currents?
You can find recent issues that have been published by Biotech Currents on Reletter by scrolling up to where it says Latest Issues. Tap on the link for any of the most recent emails or hit More Issues to see older ones.
How many subscribers does Biotech Currents have?
To see how many people subscribe to Biotech Currents, simply upgrade your Reletter account. We provide readership numbers and lots of other stats for this newsletter so you can decide if it's worth reaching out to.
How can I advertise in Biotech Currents?
Newsletter advertising can be extremely effective when it's done right. Before you pitch Biotech Currents as a potential sponsor or partner, make sure that you've done your research and checked its newsletter stats with Reletter.
Then, personalize one of our winning pitching templates and send it to the right person using the contact info provided.
How much does it cost to sponsor a publication like Biotech Currents?
Newsletter ad rates (or CPM) vary depending on many factors, including industry, number of subscribers, open rate, ad placement and more.
To find out how much an ad will cost, contact Biotech Currents using the contact information provided and ask for a copy of their media kit.
How can I find newsletters similar to Biotech Currents?
Scroll up to where it says Similar Newsletters to see other publications like Biotech Currents. You can also search our email newsletter directory to discover other newsletters that cover the topics you're interested in.
How do I contact Biotech Currents?
Reletter provides this newsletter's website URL above, where you will often find their contact information. We also provide links to associated social media accounts and pitching templates so you can reach out fast.